Newsletter subscription & archive

Biopeople member ExpreS2ion to lead European COVID-19 vaccine consortium for rapid clinical development


ExpreS2ion Biotechnologies has announced that the company will lead a consortium of European expert entities in applying for the EU Horizon 2020 and the Coalition for Epidemic Preparedness Innovations (CEPI) grant calls for COVID-19 (SARS-CoV-2) Coronavirus vaccine development.

The consortium includes all the bench-to-bedside expertise required for rapid clinical development of the COVID-19 vaccine that is already under development by ExpreS2ion.

The aim of the consortium is to develop a COVID-19 vaccine candidate, including performing proof-of-concept non-human primate (NHP) challenge studies, as well as a Phase I/IIa clinical trial with an ambitious aim to initiate clinical investigations within 12 months.

The consortium members are world-leading experts in their respective fields, covering all relevant areas of viral research and vaccine development required for rapid clinical development of a COVID-19 vaccine. This includes pre-clinical and clinically validated experience from working with similar Coronaviruses such as MERS and SARS, ExpreS2ion’s Drosophila S2 insect cell expression system, AdaptVac’s Virus-Like Particle technology and international large-scale production capacity provided by AGC Biologics, with production sites in Denmark, Germany, the US and Japan.

Read the press release here

ExpreS2ion Biotechnologies ApS was founded in 2010 as a spin out of the S2 expression platform from the Danish company Affitech A/S. The founders were scientists who had developed the platform as employees of initially Pharmexa A/S and following Affitech A/S. In 2016, ExpreS2ion Biotech Holding AB as founded.

What are you looking for?